Observational studyEuropean journal of nuclear medicine and molecular imaging2014
Comparative study of the safety of regadenoson between patients with mild/moderate chronic obstructive pulmonary disease and asthma.
Observational study in European journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Safety and tolerability of intravenous regadenoson in healthy subjects: A randomized, repeat-dose, placebo-controlled study.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2017Trial
- Assessing the Real-World Safety of Regadenoson for Myocardial Perfusion Imaging: Insights from a Comprehensive Analysis of FAERS Data.Journal of clinical medicine · 2025Article
- Stress Cardiovascular Magnetic Resonance Imaging for the Detection of Coronary Artery Disease.Reviews in cardiovascular medicine · 2023Review
- Safety of regadenoson stress testing in patients with pulmonary hypertension.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2018Article
- Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson.European journal of nuclear medicine and molecular imaging · 2017Observational
- Myocardial stress perfusion magnetic resonance: initial experience in a pediatric and young adult population using regadenoson.Pediatric radiology · 2017Article
- Cardiac CT for myocardial ischaemia detection and characterization--comparative analysis.The British journal of radiology · 2014Review
- Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge.International journal of chronic obstructive pulmonary disease · 2014Review
Corrections and comments
- Erratum issuedGarcia, Carlos Salgado [corrected to Salgado Garcia, Carlos]; Heffernan, Amelia Jimenez]
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare the safety of regadenoson, a selective agonist of A2A adenosine receptors, combined with low-level exercise, between subjects with mild/moderate chronic obstructive pulmonary disease (COPD) and asthma referred for myocardial perfusion imaging (MPI).
methodsWe studied 116 patients, of whom 67 had COPD and 49 asthma (62 % men, mean age 68.3 ± 11.3 years, range 31 - 87 years). Patient demographics, past medical history, medications, clinical symptoms during stress and changes in blood pressure (BP) and heart rate (HR) were evaluated.
resultsBoth groups were comparable with regard to hypertension, dyslipidaemia, diabetes and medications with the exception of a higher rate of use of anticholinergics in patients with COPD and of antileukotrienes in asthmatics (58.2 % vs. 28.6 % and 1.5 % vs. 14.3 %, respectively; all p < 0.01). There was a higher incidence of dyspnoea in COPD patients and of headache and feeling hot in asthmatic patients (40.3 % vs. 22.4 %, 6 % vs. 18.4 % and 10.4 % vs. 26.5 %, respectively; all p < 0.05). Although there was no difference in the incidence of other adverse events, we observed a higher frequency in asthmatics of flushing, dry mouth, sweating and fatigue (1.5 % vs. 6.1 %, 14.9 % vs. 24.5 %, 0 % vs. 4.1 % and 37.3 % vs. 49 %, respectively). Adverse events were self-limiting, except in three patients who suffered persistent dyspnoea (2 of 67 COPD patients; 1 of 49 asthma patients) requiring theophylline administration. We observed no significant changes in BP among either group, but there was a tendency towards a higher increase in systolic BP in COPD patients following regadenoson administration (148.3 ± 27.6 vs. 154.6 ± 31.0 mmHg, p = 0.056).
conclusionThis study showed a good safety profile in our series of COPD and asthma patients undergoing MPI. Regadenoson was well tolerated by all patients, with dyspnoea, headache and feeling hot showing differences between groups.
Indexed as
Identifiers
23857459What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.